Study guide

11.3 Adverse Drug Reactions & Drug Safety

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

11.3 Adverse Drug Reactions & Drug Safety

Key Takeaways Explain This Topic AI

Rawlins-Thompson Type A reactions are dose-dependent, predictable, and represent ~80% of all adverse drug reactions; Type B reactions are idiosyncratic, non-dose-dependent, and carry significant mortality.

Severe Cutaneous Adverse Reactions (SCAR) include DRESS syndrome (latency 2–8 weeks, eosinophilia ≥1.5 x 10^9/L, systemic organ involvement) and SJS/TEN (epidermal detachment and positive Nikolsky sign).

Drug-Induced Liver Injury (DILI) pattern is established using the R-ratio: R = (ALT/ALT_ULN) / (ALP/ALP_ULN); R ≥ 5 defines hepatocellular injury (e.g., paracetamol, isoniazid), whereas R ≤ 2 defines cholestatic injury (e.g., amoxicillin-clavulanate).

Acquired long QT syndrome (QTc > 500 ms) predisposes to Torsades de Pointes; immediate management of hemodynamic collapse or polymorphic VT includes IV Magnesium Sulfate 2 g bolus.

Mandatory pharmacogenomic screening prevents severe ADRs: HLA-B 5701 prior to abacavir, HLA-B 1502 prior to carbamazepine in Asian patients, and TPMT testing prior to azathioprine.

Last updated: July 2026

Adverse Drug Reactions & Drug Safety

An Adverse Drug Reaction (ADR) is defined by the World Health Organization (WHO) as any response to a drug that is noxious and unintended, occurring at doses normally used in humans for prophylaxis, diagnosis, or therapy. In hospital medicine, ADRs account for 6.5 % 6.5\% 6.5% of all acute medical admissions and complicate up to 15 % 15\% 15% of inpatient stays.

Rawlins-Thompson Classification of Adverse Drug Reactions

The standard clinical taxonomy divides ADRs into six distinct categories (Types A through F).

Type Descriptor Primary Features Representative Examples Clinical Management

Type A Augmented Dose-dependent, predictable from known pharmacology, high incidence, low mortality. Account for ≈ 80 % \approx 80\% ≈ 80% of all ADRs. - Hypoglycemia from Insulin/Gliclazide; - Bradycardia from Beta-blockers; - Bleeding from Warfarin/DOACs; - Gastritis from NSAIDs Dose reduction or drug substitution; usually does not require permanent avoidance.

Type B Bizarre (Idiosyncratic) Non-dose-dependent, unpredictable, low incidence, high mortality. Mediated by immunological hypersensitivity or genetic susceptibility. - Anaphylaxis from Penicillin; - Aplastic anemia from Chloramphenicol; - SJS/TEN from Allopurinol/Lamotrigine; - Abacavir hypersensitivity (HLA-B*5701) Immediate withdrawal; permanent absolute contraindication.

Type C Continuous (Chronic) Dose-dependent and time-dependent; associated with long-term cumulative drug exposure. - Adrenal suppression from chronic Corticosteroids; - Osteoporosis from long-term Heparin/Steroids; - Analgesic nephropathy Gradual tapering or routine monitoring during chronic therapy.

Type D Delayed Manifests months to years after drug exposure; independent of immediate serum concentration. - Secondary acute leukemia from Alkylating agents; - Teratogenesis (Phocomelia from Thalidomide, Neural tube defects from Valproate); - Tardive dyskinesia from Antipsychotics Avoid high-risk agents during pregnancy or prolonged chemotherapeutic exposures.

Type E End-of-use (Withdrawal) Occurs abruptly following drug cessation or rapid dose reduction. - Rebound hypertension after Clonidine/Beta-blocker stop; - Opioid withdrawal syndrome; - SSRI discontinuation syndrome (brain zaps, electric shocks) Reintroduce drug and perform slow, structured dose tapering.

Type F Failure of therapy Unexpected failure of treatment to achieve clinical efficacy. - Subtherapeutic dosing; - Enzyme induction (e.g., Rifampicin causing OCP failure); - Counterfeit/expired medication Increase dose, switch agent, or resolve pharmacokinetic drug-drug interactions.

Severe Cutaneous Adverse Reactions (SCAR)

Severe Cutaneous Adverse Reactions represent life-threatening Type B hypersensitivity reactions requiring immediate emergency recognition and drug discontinuation.

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Spectrum : Mucocutaneous reactions characterized by extensive keratinocyte apoptosis, epidermal detachment, and painful mucosal erosions (oral, ocular, genital).

SJS : < 10 % < 10\% < 10% Body Surface Area (BSA) epidermal detachment.

SJS/TEN Overlap : 10 − 30 % 10-30\% 10 − 30% BSA detachment.

TEN : > 30 % > 30\% > 30% BSA epidermal detachment.

Clinical Signs : Targetoid purpuric macules, positive Nikolsky sign (slippage of normal-appearing epidermis under gentle pressure).

High-Risk Culprit Drugs : Allopurinol, Sulfonamides (Co-trimoxazole), Antiepileptics (Carbamazepine, Phenytoin, Lamotrigine), NSAIDs (Oxicam class).

Management : Immediate withdrawal of suspect drug, transfer to Burn Intensive Care Unit, supportive fluid/electrolyte balance, cyclosporine or IVIG.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)

Latency : 2 to 8 weeks 2 \text{ to } 8 \text{ weeks} 2 to 8 weeks after drug initiation (characteristically longer onset than SJS/TEN).

Clinical Triad :

High fever ( > 38.5 ∘ C >38.5^\circ\text{C} > 38. 5 ∘ C ) and extensive morbilliform facial edema/rash.

Hematological abnormalities: Eosinophilia ( ≥ 1.5 × 10 9 /L \ge 1.5 \times 10^9\text{/L} ≥ 1.5 × 1 0 9 /L ) or circulating atypical lymphocytes.

Systemic organ involvement: Hepatitis ( > 50 % >50\% > 50% of cases), interstitial nephritis, pneumonitis, or myocarditis.

Pathophysiology : T-cell mediated reaction frequently associated with reactivation of latent human herpesviruses (HHV-6, HHV-7, EBV).

Culprit Drugs : Allopurinol, Carbamazepine, Phenytoin, Vancomycin, Minocycline, Sulfasalazine.

  • Organ-Specific Drug Toxicities
  • 1. Drug-Induced Liver Injury (DILI)

DILI is categorized into three patterns based on the R-ratio , calculated from initial liver biochemistry: R = Patient ALT / Upper Limit of Normal (ULN) for ALT Patient ALP / Upper Limit of Normal (ULN) for ALP R = \frac{\text{Patient ALT} / \text{Upper Limit of Normal (ULN) for ALT}}{\text{Patient ALP} / \text{Upper Limit of Normal (ULN) for ALP}} R = Patient ALP / Upper Limit of Normal (ULN) for ALP Patient ALT / Upper Limit of Normal (ULN) for ALT ​

Hepatocellular Pattern ( R ≥ 5 R \ge 5 R ≥ 5 ) : Marked elevation in ALT/AST. Triggers: Paracetamol, Isoniazid, Rifampicin, Methotrexate, Statins.

Hy’s Law : Hepatocellular DILI with ALT/AST > 3 × ULN >3\times \text{ULN} > 3 × ULN combined with Total Bilirubin > 2 × ULN >2\times \text{ULN} > 2 × ULN (in the absence of biliary obstruction or hemolysis) carries a 10 % 10\% 10% to 50 % 50\% 50% mortality rate from acute liver failure.

Cholestatic Pattern ( R ≤ 2 R \le 2 R ≤ 2 ) : Predominant elevation in ALP and Gamma-GT. Triggers: Amoxicillin-clavulanate (most common cause of DILI in Western countries), Flucloxacillin, Chlorpromazine, Combined Oral Contraceptives.

Mixed Pattern ( R = 2 to 5 R = 2 \text{ to } 5 R = 2 to 5 ) : Concurrent ALT and ALP elevations. Triggers: Phenytoin, Carbamazepine, Azathioprine.

2. Drug-Induced QT Prolongation & Torsades de Pointes (TdP)

Acquired Long QT Syndrome occurs when drugs block the delayed rectifier potassium current ( I K r I_{Kr} I Kr ​ / HERG channel), prolonging ventricular repolarization ( Q T c > 470 ms QTc > 470 \text{ ms} QT c > 470 ms in men, > 480 ms > 480 \text{ ms} > 480 ms in women). A Q T c > 500 ms QTc > 500 \text{ ms} QT c > 500 ms or an absolute increase of > 60 ms >60 \text{ ms} > 60 ms confers high risk for Torsades de Pointes (TdP) , a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation.

High-Risk Offending Drug Classes :

Antiarrhythmics : Class IA (Quinidine, Procainamide), Class IC (Flecainide), Class III (Amiodarone, Sotalol).

Psychotropics : Haloperidol, Chlorpromazine, Quetiapine, Citalopram, Escitalopram, Methadone, TCAs.

Antimicrobials : Macrolides (Erythromycin, Clarithromycin), Fluoroquinolones (Ciprofloxacin, Levofloxacin), Azole antifungals (Fluconazole).

Antiemetics : Ondansetron, Domperidone.

Acute Management of Torsades de Pointes :

Hemodynamically unstable → \rightarrow → Immediate unsynchronized DC cardioversion.

Hemodynamically stable polymorphic VT → \rightarrow → Intravenous Magnesium Sulfate 2 g bolus over 10–15 minutes (regardless of baseline serum magnesium level).

Correct hypokalemia (target K + ≥ 4.5 mmol/L K^+ \ge 4.5 \text{ mmol/L} K + ≥ 4.5 mmol/L ) and hypomagnesemia.

Refractory cases → \rightarrow → Overdrive atrial/ventricular pacing or Isoprenaline infusion (to increase heart rate and shorten QTc).

3. Drug-Induced Nephrotoxicity

Acute Tubular Necrosion (ATN) : Aminoglycosides, Cisplatin, Amphotericin B, Radiocontrast media.

Acute Interstitial Nephritis (AIN) : Classic triad of fever, maculopapular rash, and eosinophilia/eosinophiluria. Triggers: NSAIDs, Proton Pump Inhibitors (Omeprazole), Penicillins, Cephalosporins, Loop diuretics.

Hemodynamic AKI : ACE inhibitors/ARBs (reduce efferent arteriolar tone) combined with NSAIDs (inhibit prostaglandin-mediated afferent arteriolar vasodilation) and diuretics ("Triple Whammy").

Pharmacogenomics & Pre-Prescribing Safety Screening

Pharmacogenomic testing identifies genetic variations that alter drug metabolism or trigger severe hypersensitivity reactions.

Clinical Table: Essential Pharmacogenomic Screening Markers

Genetic Marker Drug Involved Associated Clinical Risk / Reaction Clinical Recommendation

HLA-B*5701 Abacavir (NRTI) Multi-organ hypersensitivity reaction (fever, rash, GI distress, respiratory collapse). Mandatory screening prior to starting abacavir. Positive test is an absolute contraindication.

HLA-B*1502 Carbamazepine Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in Asian ancestry. Mandatory screening in patients of Han Chinese, Thai, South/Southeast Asian origin before carbamazepine.

HLA-B*5801 Allopurinol Severe Cutaneous Adverse Reactions (SCAR/SJS) in renal impairment. Screen high-risk populations (Han Chinese, Thai, Korean with CKD) prior to allopurinol initiation.

TPMT Azathioprine / 6-MP Profound, fatal bone marrow aplasia in homozygous deficient individuals. Check TPMT activity before starting treatment. If deficient, avoid or reduce dose by 90 % 90\% 90% .

DPYD 5-Fluorouracil / Capecitabine Life-threatening mucositis, neutropenia, and neurotoxicity due to DPD enzyme deficiency. Screen DPYD variants before fluoropyrimidine chemotherapy.

G6PD Deficiency Primaquine, Rasburicase, Dapsone, Nitrofurantoin, Cotrimoxazole Acute intravascular hemolysis, hemoglobinuria, and Heinz body formation. Screen G6PD levels before prescribing oxidative medications.

Pharmacovigilance & Causality Assessment

Naranjo Causality Scale : Evaluates the probability of an ADR based on 10 standardized questions (dose-response, re-challenge, alternative causes). Score ≥ 9 \ge 9 ≥ 9 = Definite ADR; 5 − 8 5-8 5 − 8 = Probable ADR; 1 − 4 1-4 1 − 4 = Possible ADR; ≤ 0 \le 0 ≤ 0 = Doubtful.

Yellow Card Scheme (MHRA / HPRA) : National reporting system for adverse drug reactions.

Black Triangle ( ▼ \blacktriangledown ▼ ) Symbols : Signifies newly licensed drugs or vaccines subject to intensive surveillance. Clinicians MUST report all suspected adverse reactions (both minor and severe) for black triangle medications.

For established medicines, clinicians should report all serious suspected ADRs (fatal, life-threatening, disabling, or resulting in hospitalization).

Exam Pearls

MRCPI Exam Pearl : Screening for HLA-B*5701 is mandatory prior to initiating Abacavir. If positive, abacavir must NEVER be prescribed; rechallenging a sensitized patient causes fatal anaphylactoid cardiovascular collapse.

MRCPI Exam Pearl : In suspected Drug-Induced Liver Injury (DILI), Hy's Law specifies that jaundice (Total Bilirubin > 2 × ULN > 2\times \text{ULN} > 2 × ULN ) accompanying hepatocellular injury (ALT > 3 × ULN > 3\times \text{ULN} > 3 × ULN ) carries a 10 − 50 % 10-50\% 10 − 50% mortality rate from acute liver failure. Immediate drug cessation is paramount.